271 related articles for article (PubMed ID: 9587683)
1. Endocrine therapy of prostate cancer.
Bare RL; Torti FM
Cancer Treat Res; 1998; 94():69-87. PubMed ID: 9587683
[TBL] [Abstract][Full Text] [Related]
2. Hormone therapy in advanced prostate cancer.
Forster TH; Stoffel F; Gasser TC
Front Radiat Ther Oncol; 2002; 36():49-65. PubMed ID: 11842755
[No Abstract] [Full Text] [Related]
3. Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials.
Bolla M; de Reijke TM; Zurlo A; Collette L
Front Radiat Ther Oncol; 2002; 36():81-6. PubMed ID: 11842758
[No Abstract] [Full Text] [Related]
4. Hormone therapy of prostatic bone metastases.
Huben RP
Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
[TBL] [Abstract][Full Text] [Related]
5. Role of secondary hormonal therapy in the management of recurrent prostate cancer.
Ryan CJ; Small EJ
Urology; 2003 Dec; 62 Suppl 1():87-94. PubMed ID: 14747046
[TBL] [Abstract][Full Text] [Related]
6. Intermittent androgen ablation as a treatment for prostate cancer.
Wolff JM
Front Radiat Ther Oncol; 2002; 36():66-71. PubMed ID: 11842756
[No Abstract] [Full Text] [Related]
7. [Hormono-radiotherapy of non-metastatic prostate cancers].
Richaud P; Mazeron JJ
Cancer Radiother; 2002 May; 6(3):175-82. PubMed ID: 12116843
[TBL] [Abstract][Full Text] [Related]
8. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
Hellerstedt B
Urology; 2003 Dec; 62 Suppl 1():79-86. PubMed ID: 14747045
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
Koutsilieris M; Bogdanos J; Milathianakis C; Dimopoulos P; Dimopoulos T; Karamanolakis D; Halapas A; Tenta R; Katopodis H; Papageorgiou E; Pitulis N; Pissimissis N; Lembessis P; Sourla A
Expert Opin Investig Drugs; 2006 Jul; 15(7):795-804. PubMed ID: 16787142
[TBL] [Abstract][Full Text] [Related]
10. Endocrine treatment of prostate cancer: standard treatment and new perspectives.
Boccardo F; Pace M
In Vivo; 1993; 7(5):423-4. PubMed ID: 8110985
[TBL] [Abstract][Full Text] [Related]
11. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
Pienta KJ;
Urology; 2003 Dec; 62 Suppl 1():95-101. PubMed ID: 14747047
[TBL] [Abstract][Full Text] [Related]
12. [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].
Pinto F; Calarco A; Totaro A; Sacco E; Volpe A; Racioppi M; D'Addessi A; Bassi PF
Urologia; 2010; 77(2):71-83. PubMed ID: 20890863
[TBL] [Abstract][Full Text] [Related]
13. Complete androgen blockade for the treatment of prostate cancer.
Labrie F; Dupont A; Belanger A
Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
[No Abstract] [Full Text] [Related]
14. Neoadjuvant androgen suppression and external beam radiation therapy.
Zietman AL; Smith CT
Front Radiat Ther Oncol; 2002; 36():87-98. PubMed ID: 11842759
[No Abstract] [Full Text] [Related]
15. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
Tsukamoto S; Akaza H
Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
[TBL] [Abstract][Full Text] [Related]
16. Advanced prostate cancer. Hormonal treatment.
de la Haba-RodrÃguez J
Tunis Med; 2005 Dec; 83 Suppl 12():71-3. PubMed ID: 16430072
[No Abstract] [Full Text] [Related]
17. The androgen receptor for the radiation oncologist.
Quero L; Rozet F; Beuzeboc P; Hennequin C
Cancer Radiother; 2015 May; 19(3):220-7. PubMed ID: 25921704
[TBL] [Abstract][Full Text] [Related]
18. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
Berenguer Sánchez A
Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
[No Abstract] [Full Text] [Related]
19. [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate].
Lopez S; Simon JM; Mazeron JJ
Bull Cancer; 2009 Mar; 96(3):261-70. PubMed ID: 19318304
[TBL] [Abstract][Full Text] [Related]
20. P450-dependent enzymes as targets for prostate cancer therapy.
De Coster R; Wouters W; Bruynseels J
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
